[The prognosis and control of the efficacy of heparin therapy in patients with diabetic glomerulosclerosis]. / Prognozirovanie i kontrol' éffektivnosti geparinoterapii u bol'nykh diabeticheskim glomerulosklerozom.

3-week heparin treatment (25000 U/day) of 38 patients with diabetic glomerulosclerosis (DGS) produced positive results in 31 of them, was ineffective in 5 patients and induced complications in 2 cases. Prognostic criteria of heparin treatment efficacy basing on hemostatic changes on day 7 have been developed. Hemostasis was controlled most effectively in patients receiving heparin by a new graphic turbidimetric method capable of objective registration of clotting and fibrinolysis in one plasma portion. Because individual sensitivity to heparin widely varies and this variability manifests as early as first days of treatment, control over hemostasis system in heparin day dose 25000 U/day is advisable before treatment, on treatment day 3, 7 and on aftertreatment day 2.

[Changes in thrombocytic hemostasis in patients with diabetic glomerulosclerosis]. / Izmeneniia trombotsitarnogo gemostaza u bol'nykh diabeticheskim glomerulosklerozom.

Indices of thrombocytic hemostasis were determined in 40 patients with diabetic glomerulosclerosis. It was found that patients suffering of diabetic glomerulosclerosis with chronic renal insufficiency showed signs of hypercoagulemia while changes of the thrombocytic hemostasis become of diverse values. There was a high correlation of hemostasis changes and clinical manifestations of diabetes mellitus and diabetic glomerulosclerosis. Three tests are recommended for treatment choice: hemolysate-aggregation test, determination of soluble complexes of monomer fibrin and fibrin-splitting product.

[A comparative evaluation of methods for determining the activity of rheumatic diseases]. / Sravnitel'naia otsenka nekotorykh metodov opredeleniia aktivnosti revmaticheskikh zabolevanii.

The blood concentration of soluble complexes of monomere fibrin (SCMF), fibrin/fibrinogen splitting products (FSP) and sigma-ESB were determined in 11 patients with rheumatic diseases showing an articular syndrome. The authors revealed the diagnostic significance of SCMF in arthritis of any etiology and FSP in rheumatic diseases with systemic manifestations.

[Indices of the blood fibrinolytic system in osteoarthrosis and rheumatoid arthritis]. / Pokazateli fibrinoliticheskoi sistemy krovi pri osteoartroze i revmatoidnom artrite.

The fibrinolytic system of the blood was studied in 46 patients with osteoarthrosis (OA) associated with reactive synovitis or without it, 44 patients with rheumatoid arthritis (RA) without visceral manifestations. It was found that a slowing of enzymatic, nonenzymatic and XIIa-dependent fibrinolysis is typical of RA but not of OA. Products of fibrin breaking in the general blood flow were absent in patients with OA but may be observed in RA. Increase of the level of fibrin monomers (FM) in the blood are observed in OA with reactive synovitis. The concentration of FM in the blood in RA and OA with reactive synovitis is an informative and dynamic sign of the activity of the inflammatory process and efficacy of treatment.

[The fibrinogen-fibrin-fibrinolysis system in rheumatoid arthritis]. / Sistema fibrinogen-fibrin-fibrinoliz pri revmatoidnom artrite.

The enzymatic, nonenzymatic and XIIa-dependent fibrinolysis was inhibited. In RA without systemic manifestations the main cause of appearance of soluble complexes of monomeric fibrins (SCMF) in the blood is a local activation of coagulation in the inflamed joint tissues. It is suggested that an increase of SCMF concentration in the blood in patients with RA is a reliable and dynamic index of the activity of the inflammatory process.